54.10
price down icon1.55%   -0.85
 
loading

Vaxcyte Inc 주식(PCVX)의 최신 뉴스

pulisher
Feb 13, 2026

Is now the right time to enter Vaxcyte Inc.Market Activity Report & Safe Capital Growth Tips - mfd.ru

Feb 13, 2026
pulisher
Feb 11, 2026

Vaxcyte (PCVX) Initiates Phase 3 Trial for VAX-31 Vaccine in Adu - GuruFocus

Feb 11, 2026
pulisher
Feb 11, 2026

Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines - The Manila Times

Feb 11, 2026
pulisher
Feb 11, 2026

Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial - GlobeNewswire

Feb 11, 2026
pulisher
Feb 11, 2026

Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 - Sahm

Feb 11, 2026
pulisher
Feb 10, 2026

Vaxcyte, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 - Quiver Quantitative

Feb 10, 2026
pulisher
Feb 10, 2026

Vaxcyte to Report Fourth Quarter and Full Year 2025 - GlobeNewswire

Feb 10, 2026
pulisher
Feb 10, 2026

IPO Launch: What is the target price for Vaxcyte Inc stockMarket Risk Report & Safe Swing Trade Setups - baoquankhu1.vn

Feb 10, 2026
pulisher
Feb 10, 2026

Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Feb 10, 2026
pulisher
Feb 09, 2026

Valuation Update: Is Vaxcyte Inc affected by consumer sentimentSwing Trade & Fast Gaining Stock Strategy Reports - baoquankhu1.vn

Feb 09, 2026
pulisher
Feb 08, 2026

Vaxcyte, Inc. $PCVX Shares Bought by Federated Hermes Inc. - MarketBeat

Feb 08, 2026
pulisher
Feb 08, 2026

Aug Wrap: Does Stepan Company have consistent dividend growth2025 AllTime Highs & Fast Gain Swing Alerts - baoquankhu1.vn

Feb 08, 2026
pulisher
Feb 08, 2026

How Investors May Respond To Vaxcyte (PCVX) Raising $550 Million To Fund Pneumococcal Vaccine Pipeline - Sahm

Feb 08, 2026
pulisher
Feb 06, 2026

Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit - 富途牛牛

Feb 06, 2026
pulisher
Feb 05, 2026

Commit To Buy Vaxcyte At $45, Earn 19.3% Annualized Using Options - Nasdaq

Feb 05, 2026
pulisher
Feb 04, 2026

Technical Reactions to PCVX Trends in Macro Strategies - Stock Traders Daily

Feb 04, 2026
pulisher
Feb 03, 2026

Vaxcyte closes $632.5 million public offering of common stock By Investing.com - Investing.com India

Feb 03, 2026
pulisher
Feb 03, 2026

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times

Feb 03, 2026
pulisher
Feb 03, 2026

Is It Time To Reassess Vaxcyte (PCVX) After Recent Share Price Recovery - Yahoo Finance

Feb 03, 2026
pulisher
Feb 02, 2026

Assessing Vaxcyte (PCVX) Valuation After Recent Share Price Momentum - Yahoo Finance

Feb 02, 2026
pulisher
Feb 02, 2026

Vaxcyte Funding And Late-Stage Trials Put Valuation In Focus - Yahoo Finance

Feb 02, 2026
pulisher
Feb 02, 2026

Vaxcyte (NASDAQ:PCVX) Stock Price Up 8.1%Time to Buy? - MarketBeat

Feb 02, 2026
pulisher
Feb 02, 2026

Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring A Potential 90.61% Upside For Investors - DirectorsTalk Interviews

Feb 02, 2026
pulisher
Feb 02, 2026

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Investing News Network

Feb 02, 2026
pulisher
Feb 02, 2026

Vaxcyte Closes Public Offering of Shares - marketscreener.com

Feb 02, 2026
pulisher
Feb 02, 2026

Vaxcyte Completes Public Equity Offering, Bolstering Capital Position - TipRanks

Feb 02, 2026
pulisher
Feb 02, 2026

Vaxcyte closes $632.5 million public offering of common stock - Investing.com

Feb 02, 2026
pulisher
Feb 02, 2026

Vaxcyte, Inc. Completes $632.5 Million Public Offering of Common Stock - Quiver Quantitative

Feb 02, 2026
pulisher
Feb 02, 2026

Guggenheim Reiterates Buy Rating on Vaxcyte (PCVX) at $116 Targe - GuruFocus

Feb 02, 2026
pulisher
Feb 02, 2026

Vaxcyte (NASDAQ:PCVX) Earns Buy Rating from Guggenheim - MarketBeat

Feb 02, 2026
pulisher
Feb 01, 2026

Sentiment Recap: Whats the RSI of Vaxcyte Inc stock2025 Retail Activity & AI Driven Stock Reports - baoquankhu1.vn

Feb 01, 2026
pulisher
Feb 01, 2026

Top Biotech Stocks To Follow TodayFebruary 1st - MarketBeat

Feb 01, 2026
pulisher
Jan 31, 2026

Vaxcyte launches proposed $500M public offering of stock, warrants - MSN

Jan 31, 2026
pulisher
Jan 30, 2026

Vaxcyte prices $550 million public offering of common stock By Investing.com - Investing.com Nigeria

Jan 30, 2026
pulisher
Jan 30, 2026

Eikon aims high for NASDAQ listing: Public Equity Report - BioCentury

Jan 30, 2026
pulisher
Jan 30, 2026

Latham & Watkins Advises on Vaxcyte’s US$550 Million Public Offering - Latham & Watkins LLP

Jan 30, 2026
pulisher
Jan 30, 2026

Vaxcyte launches $500 million public offering of common stock By Investing.com - au.investing.com

Jan 30, 2026
pulisher
Jan 30, 2026

Biotech Stocks To Follow TodayJanuary 30th - MarketBeat

Jan 30, 2026
pulisher
Jan 30, 2026

PCVX Increases Common Stock Offering to $550 Million - GuruFocus

Jan 30, 2026
pulisher
Jan 30, 2026

Vaxcyte (NASDAQ:PCVX) Shares Gap UpStill a Buy? - MarketBeat

Jan 30, 2026
pulisher
Jan 30, 2026

Vaccine maker looks to raise half a billion dollars to attack an $8 billion market - The Business Journals

Jan 30, 2026
pulisher
Jan 30, 2026

Vaxcyte edges higher after upsized $550 mln equity raise - TradingView

Jan 30, 2026
pulisher
Jan 30, 2026

Vaxcyte Secures $550 Million to Advance Vaccine Pipeline and Manufacturing - AD HOC NEWS

Jan 30, 2026
pulisher
Jan 30, 2026

Vaxcyte Prices $550 Million Common Stock Offering - marketscreener.com

Jan 30, 2026
pulisher
Jan 30, 2026

Vaxcyte Announces Pricing of $550 Million Public Offering - Investing News Network

Jan 30, 2026
pulisher
Jan 29, 2026

Vaxcyte prices $550 million public offering of common stock - Investing.com

Jan 29, 2026
pulisher
Jan 29, 2026

Vaxcyte sells 11M new shares in $550M stock offering at $50 - stocktitan.net

Jan 29, 2026
pulisher
Jan 29, 2026

PCVX Offering Managed by Top Financial Firms - GuruFocus

Jan 29, 2026
pulisher
Jan 29, 2026

Vaxcyte (PCVX) Launches Share Offering Priced at $50 - GuruFocus

Jan 29, 2026
$26.45
price down icon 1.12%
$45.19
price up icon 0.87%
$101.10
price up icon 0.35%
$105.87
price up icon 0.10%
$148.75
price up icon 1.77%
biotechnology ONC
$346.07
price down icon 0.10%
자본화:     |  볼륨(24시간):